[3H]MRS 1754, a selective antagonist radioligand for A2B adenosine receptors

Biochemical Pharmacology

Volumn 61, Issue 6, 2001, Pages 657-663

  Ji, Xiao Duoseqkat ^a   Kim, Yong Chul ^a   Ahern, David G ^b   Linden, Joel ^c   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NEN Life Science Products   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adenosine analogues; G protein coupled receptors; Tritium purines; Xanthines

Indexed keywords

1,3 DIALLYL 8 CYCLOHEXYLXANTHINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 N 4 SULFOPHENYLADENOSINE; 6 N CYCLOPENTYLADENOSINE; 8 (4 CARBOXYMETHOXYPHENYL) 1,3 DIPROPYLXANTHINE; 8 [4 (2 AMINOETHYLCARBAMOYL)METHOXYPHENYL] 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ALLOXAZINE; CALCIUM ION; EDETIC ACID; EGTAZIC ACID; ENPROFYLLINE; MAGNESIUM ION; MANGANESE; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE H 3; PHENYLISOPROPYLADENOSINE; RADIOLIGAND; SODIUM ION; THEOPHYLLINE; TRITIUM; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE; ZINC ION; ACETAMIDE DERIVATIVE; ADENOSINE RECEPTOR; N (4 CYANOPHENYL) 2 (4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL) PHENOXY)ACETAMIDE; N-(4-CYANOPHENYL)-2-(4-(2,3,6,7-TETRAHYDRO-2,6-DIOXO-1,3-DIPROPYL-1H-PURIN-8-YL)-PHENOXY)ACETAMIDE; PURINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CHEMICAL REACTION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; EMBRYO; EQUILIBRIUM CONSTANT; HUMAN; HUMAN CELL; MEMBRANE BINDING; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRUCTURE ACTIVITY RELATION; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; RADIOASSAY; SYNTHESIS;

ACETAMIDES; CELLS, CULTURED; HUMANS; PURINES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTOR, ADENOSINE A2B; RECEPTORS, PURINERGIC P1; TRITIUM;

EID: 0035866550     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00531-7     Document Type: Article

References (26)

1. Molecular biology of recombinant adenosine receptors
2. Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines
3. 2A-adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: Characterization with radioligand binding and by activation of adenylate cyclase
4. 1 via a cholera toxin-sensitive mechanism in human erythroleukemia cells
5. Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells
6. 2B adenosine receptors
7. 2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity
8. 2B receptors
9. Molecular characterization of recombinant human adenosine receptors
10. 2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia
11. 2B receptors
12. 2B adenosine receptors
13. 2B adenosine receptors
14. 2B adenosine receptors
15. 3-adenosine receptors
16. 50) of an enzymatic reaction
17. 3 adenosine receptor-selective antagonists
18. 3 receptor subtypes
19. 2a selective adenosine receptor antagonist
20. 2b adenosine receptor in NIH 3T3 fibroblasts
21. 1 adenosine receptors
22. 2B receptor as part of a search for potent and selective agonists
23. 2B receptors: A novel therapeutic target in asthma?
24. Adenosine receptor ligands: Potential as therapeutic agents in asthma and COPD
25. 2B receptor
26. Synthesis and characterization of potent ligands at human recombinant adenosine receptors